{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:06:49Z","timestamp":1792843609241,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12022-025-09876-x","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T08:48:17Z","timestamp":1756975697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diagnostic Evaluation of Anaplastic Thyroid Carcinoma in Core Biopsy Specimens: Morphologic, Immunohistochemical, Molecular, and Therapeutic Considerations"],"prefix":"10.1007","volume":"36","author":[{"given":"Maria Cristina","family":"Riascos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine A.","family":"Barletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"issue":"4","key":"9876_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1530\/ERC-15-0445","volume":"23","author":"Y Mao","year":"2016","unstructured":"Mao Y, Xing M. Recent incidences and differential trends of thyroid cancer in the USA. Endocr Relat Cancer. 2016;23(4):313-22.","journal-title":"Endocr Relat Cancer."},{"issue":"13","key":"9876_CR2","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.2017.2719","volume":"317","author":"H Lim","year":"2017","unstructured":"Lim H, Devesa SS, Sosa JA, et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA. 2017;317(13):1338-48.","journal-title":"JAMA."},{"issue":"7","key":"9876_CR3","first-page":"1330","volume":"103","author":"E Kebebew","year":"2005","unstructured":"Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103(7):1330-5.","journal-title":"Treatment outcome and prognostic factors. Cancer."},{"issue":"11","key":"9876_CR4","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1089\/thy.2010.0332","volume":"21","author":"J Akaishi","year":"2011","unstructured":"Akaishi J, Sugino K, Kitagawa W, et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid. 2011;21(11):1183-9.","journal-title":"Thyroid."},{"issue":"10","key":"9876_CR5","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1089\/thy.2020.0086","volume":"30","author":"B Xu","year":"2020","unstructured":"Xu B, Fuchs T, Dogan S, et al. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. Thyroid. 2020;30(10):1505-17.","journal-title":"Thyroid."},{"issue":"5","key":"9876_CR6","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1089\/thy.2016.0395","volume":"27","author":"SN Rao","year":"2017","unstructured":"Rao SN, Zafereo M, Dadu R, et al. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid. 2017;27(5):672-81.","journal-title":"Thyroid."},{"issue":"3","key":"9876_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible KC, Kebebew E, Brierley J, et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid. 2021;31(3):337-86.","journal-title":"Thyroid."},{"issue":"2","key":"9876_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/cncr.32548","volume":"126","author":"D Fan","year":"2020","unstructured":"Fan D, Ma J, Bell AC, et al. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. Cancer. 2020;126(2):444-52.","journal-title":"Cancer."},{"issue":"1","key":"9876_CR9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s12020-023-03662-7","volume":"85","author":"Y Yin","year":"2024","unstructured":"Yin Y, Wang L, Huang C. Surgery combined with adjuvant radiation and chemotherapy prolonged overall survival in stage IVC anaplastic thyroid cancer: a SEER-based analysis. Endocrine. 2024;85(1):250-7.","journal-title":"Endocrine."},{"issue":"3","key":"9876_CR10","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.5858\/2005-129-e55-RTOTTG","volume":"129","author":"ML Lai","year":"2005","unstructured":"Lai ML, Faa G, Serra S, et al. Rhabdoid tumor of the thyroid gland: a variant of anaplastic carcinoma. Arch Pathol Lab Med. 2005;129(3):e55-7.","journal-title":"Arch Pathol Lab Med."},{"issue":"5","key":"9876_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/dc.23254","volume":"43","author":"G Feng","year":"2015","unstructured":"Feng G, Laskin WB, Chou PM, Lin X. Anaplastic thyroid carcinoma with rhabdoid features. Diagn Cytopathol. 2015;43(5):416-20.","journal-title":"Diagn Cytopathol."},{"issue":"2","key":"9876_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/00000478-199102000-00009","volume":"15","author":"MJ Gaffey","year":"1991","unstructured":"Gaffey MJ, Lack EE, Christ ML, Weiss LM. Anaplastic thyroid carcinoma with osteoclast-like giant cells. A clinicopathologic, immunohistochemical, and ultrastructural study. Am J Surg Pathol. 1991;15(2):160-8.","journal-title":"Am J Surg Pathol."},{"issue":"2","key":"9876_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1385\/EP:12:2:157","volume":"12","author":"JC Canos","year":"2001","unstructured":"Canos JC, Serrano A, Matias-Guiu X. Paucicellular variant of anaplastic thyroid carcinoma: report of two cases. Endocr Pathol. 2001;12(2):157-61.","journal-title":"Endocr Pathol."},{"issue":"4","key":"9876_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/ajcp\/105.4.388","volume":"105","author":"SK Wan","year":"1996","unstructured":"Wan SK, Chan JK, Tang SK. Paucicellular variant of anaplastic thyroid carcinoma. A mimic of Reidel's thyroiditis. Am J Clin Pathol. 1996;105(4):388-93.","journal-title":"Am J Clin Pathol."},{"issue":"3","key":"9876_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s12022-020-09627-0","volume":"31","author":"KS Wong","year":"2020","unstructured":"Wong KS, Lorch JH, Alexander EK, et al. Histopathologic Features and Clinical Outcome of Anaplastic Thyroid Carcinoma with a Minor Anaplastic Component. Endocr Pathol. 2020;31(3):283-90.","journal-title":"Endocr Pathol."},{"issue":"5","key":"9876_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/COC.0b013e31816a61f3","volume":"31","author":"J Chen","year":"2008","unstructured":"Chen J, Tward JD, Shrieve DC, Hitchcock YJ. Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002. Am J Clin Oncol. 2008;31(5):460-4.","journal-title":"Am J Clin Oncol."},{"key":"9876_CR17","doi-asserted-by":"crossref","unstructured":"Glaser SM, Mandish SF, Gill BS, et al. Anaplastic thyroid cancer: Prognostic factors, patterns of care, and overall survival. Head Neck. 2016;38 Suppl 1(E2083\u201390.","DOI":"10.1002\/hed.24384"},{"key":"9876_CR18","doi-asserted-by":"crossref","unstructured":"De Felice F, Moscatelli E, Orelli S, et al. Primary thyroid angiosarcoma: A systematic review. Oral Oncol. 2018;82(48\u201352.","DOI":"10.1016\/j.oraloncology.2018.05.004"},{"issue":"3","key":"9876_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12022-013-9253-z","volume":"24","author":"A Kaur","year":"2013","unstructured":"Kaur A, Didolkar MS, Thomas A. Angiosarcoma of the thyroid: a case report with review of the literature. Endocr Pathol. 2013;24(3):156-61.","journal-title":"Endocr Pathol."},{"issue":"4","key":"9876_CR20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1089\/thy.2007.0276","volume":"18","author":"TS Wang","year":"2008","unstructured":"Wang TS, Ocal IT, Oxley K, Sosa JA. Primary leiomyosarcoma of the thyroid gland. Thyroid. 2008;18(4):425-8.","journal-title":"Thyroid."},{"issue":"12","key":"9876_CR21","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1097\/PAS.0000000000001967","volume":"46","author":"JA Barletta","year":"2022","unstructured":"Barletta JA, Gilday SD, Afkhami M, et al. NUTM1 -rearranged Carcinoma of the Thyroid : A Distinct Subset of NUT Carcinoma Characterized by Frequent NSD3 - NUTM1 Fusions. Am J Surg Pathol. 2022;46(12):1706-15.","journal-title":"Am J Surg Pathol."},{"issue":"2","key":"9876_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s12022-021-09700-2","volume":"33","author":"DB Allison","year":"2022","unstructured":"Allison DB, Rueckert J, Cornea V, et al. Thyroid Carcinoma with NSD3::NUTM1 Fusion: a Case with Thyrocyte Differentiation and Colloid Production. Endocr Pathol. 2022;33(2):315-26.","journal-title":"Endocr Pathol."},{"issue":"7","key":"9876_CR23","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1097\/PAS.0b013e318198d666","volume":"33","author":"H Haack","year":"2009","unstructured":"Haack H, Johnson LA, Fry CJ, et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol. 2009;33(7):984-91.","journal-title":"Am J Surg Pathol."},{"key":"9876_CR24","doi-asserted-by":"crossref","unstructured":"Zala A, Berhane T, Juhlin CC, et al. Riedel Thyroiditis. J Clin Endocrinol Metab. 2020;105(9):","DOI":"10.1210\/clinem\/dgaa468"},{"key":"9876_CR25","doi-asserted-by":"crossref","unstructured":"Deeken-Draisey A, Yang GY, Gao J, Alexiev BA. Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular single-institution study. Hum Pathol. 2018;82(140\u20138.","DOI":"10.1016\/j.humpath.2018.07.027"},{"issue":"2","key":"9876_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/1097-0142(19900715)66:2<321::AID-CNCR2820660221>3.0.CO;2-A","volume":"66","author":"YS Venkatesh","year":"1990","unstructured":"Venkatesh YS, Ordonez NG, Schultz PN, et al. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer. 1990;66(2):321-30.","journal-title":"Cancer."},{"issue":"4","key":"9876_CR27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12022-024-09833-0","volume":"35","author":"D Nkosi","year":"2024","unstructured":"Nkosi D, Crowe WE, Altman BJ, et al. SATB2 is an Emergent Biomarker of Anaplastic Thyroid Carcinoma: A Series with Comprehensive Biomarker and Molecular Studies. Endocr Pathol. 2024;35(4):432-41.","journal-title":"Endocr Pathol."},{"issue":"12","key":"9876_CR28","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/j.humpath.2011.02.004","volume":"42","author":"JA Bishop","year":"2011","unstructured":"Bishop JA, Sharma R, Westra WH. PAX8 immunostaining of anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck. Hum Pathol. 2011;42(12):1873-7.","journal-title":"Hum Pathol."},{"issue":"1","key":"9876_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s12022-025-09858-z","volume":"36","author":"F Haq","year":"2025","unstructured":"Haq F, Bychkov A, Mete O, et al. Identification of Specific Biomarkers for Anaplastic Thyroid Carcinoma Through Spatial Transcriptomic and Immunohistochemical Profiling. Endocr Pathol. 2025;36(1):14.","journal-title":"Endocr Pathol."},{"issue":"2","key":"9876_CR30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/his.14144","volume":"77","author":"TY Chen","year":"2020","unstructured":"Chen TY, Lorch JH, Wong KS, Barletta JA. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma. Histopathology. 2020;77(2):314-20.","journal-title":"Histopathology."},{"issue":"3","key":"9876_CR31","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052-66.","journal-title":"J Clin Invest."},{"issue":"9","key":"9876_CR32","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/modpathol.2010.117","volume":"23","author":"S Asioli","year":"2010","unstructured":"Asioli S, Erickson LA, Righi A, et al. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol. 2010;23(9):1269-78.","journal-title":"Mod Pathol."},{"issue":"4","key":"9876_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12022-024-09836-x","volume":"35","author":"O Mete","year":"2024","unstructured":"Mete O, Boucher A, Schrader KA, et al. Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management. Endocr Pathol. 2024;35(4):293-308.","journal-title":"Endocr Pathol."},{"key":"9876_CR34","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, Thyroid Carcinoma 2025 [updated March 27, 2025. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thyroid.pdf."},{"issue":"5","key":"9876_CR35","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1053\/j.semdp.2015.02.010","volume":"32","author":"LL Ritterhouse","year":"2015","unstructured":"Ritterhouse LL, Barletta JA. BRAF V600E mutation-specific antibody: A review. Semin Diagn Pathol. 2015;32(5):400-8.","journal-title":"Semin Diagn Pathol."},{"issue":"8","key":"9876_CR36","doi-asserted-by":"publisher","first-page":"E1414","DOI":"10.1210\/jc.2013-1408","volume":"98","author":"RA Ghossein","year":"2013","unstructured":"Ghossein RA, Katabi N, Fagin JA. Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. J Clin Endocrinol Metab. 2013;98(8):E1414-21.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"9876_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2018;36(1):7-13.","journal-title":"J Clin Oncol."},{"issue":"4","key":"9876_CR38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022;33(4):406-15.","journal-title":"Ann Oncol."},{"issue":"10","key":"9876_CR39","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1097\/PAS.0000000000002284","volume":"48","author":"S Agarwal","year":"2024","unstructured":"Agarwal S, Jung CK, Gaddam P, et al. PD-L1 Expression and Its Modulating Factors in Anaplastic Thyroid Carcinoma: A Multi-institutional Study. Am J Surg Pathol. 2024;48(10):1233-44.","journal-title":"Am J Surg Pathol."},{"issue":"23","key":"9876_CR40","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/JCO.19.02727","volume":"38","author":"J Capdevila","year":"2020","unstructured":"Capdevila J, Wirth LJ, Ernst T, et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020;38(23):2620-7.","journal-title":"J Clin Oncol."},{"issue":"4","key":"9876_CR41","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12022-024-09832-1","volume":"35","author":"M Boruah","year":"2024","unstructured":"Boruah M, Agarwal S, Mir RA, et al. Unravelling the Reasons Behind Limited Response to Anti-PD Therapy in ATC: A Comprehensive Evaluation of Tumor-Infiltrating Immune Cells and Checkpoints. Endocr Pathol. 2024;35(4):419-31.","journal-title":"Endocr Pathol."},{"issue":"3","key":"9876_CR42","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/thy.2023.0573","volume":"34","author":"S Hamidi","year":"2024","unstructured":"Hamidi S, Iyer PC, Dadu R, et al. Checkpoint Inhibition in Addition to Dabrafenib\/Trametinib for BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2024;34(3):336-46.","journal-title":"Thyroid."},{"issue":"3","key":"9876_CR43","doi-asserted-by":"publisher","first-page":"113826","DOI":"10.1016\/j.celrep.2024.113826","volume":"43","author":"PYF Zeng","year":"2024","unstructured":"Zeng PYF, Prokopec SD, Lai SY, et al. The genomic and evolutionary landscapes of anaplastic thyroid carcinoma. Cell Rep. 2024;43(3):113826.","journal-title":"Cell Rep."},{"issue":"5","key":"9876_CR44","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1053\/j.semdp.2020.06.005","volume":"37","author":"J Yang","year":"2020","unstructured":"Yang J, Barletta JA. Anaplastic thyroid carcinoma. Semin Diagn Pathol. 2020;37(5):248-56.","journal-title":"Semin Diagn Pathol."},{"issue":"6","key":"9876_CR45","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/hed.25634","volume":"41","author":"SA Khan","year":"2019","unstructured":"Khan SA, Ci B, Xie Y, et al. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head Neck. 2019;41(6):1928-34.","journal-title":"Head Neck."},{"issue":"13","key":"9876_CR46","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","volume":"24","author":"N Pozdeyev","year":"2018","unstructured":"Pozdeyev N, Gay LM, Sokol ES, et al. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin Cancer Res. 2018;24(13):3059-68.","journal-title":"Clin Cancer Res."},{"issue":"5","key":"9876_CR47","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1089\/thy.2018.0716","volume":"29","author":"KS Wong","year":"2019","unstructured":"Wong KS, Lorch JH, Alexander EK, et al. Clinicopathologic Features of Mismatch Repair-Deficient Anaplastic Thyroid Carcinomas. Thyroid. 2019;29(5):666-73.","journal-title":"Thyroid."},{"issue":"6","key":"9876_CR48","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/his.13942","volume":"75","author":"H Duan","year":"2019","unstructured":"Duan H, Li Y, Hu P, et al. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing. Histopathology. 2019;75(6):890-9.","journal-title":"Histopathology."},{"issue":"9","key":"9876_CR49","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1089\/thy.2019.0477","volume":"30","author":"D Dias-Santagata","year":"2020","unstructured":"Dias-Santagata D, Lennerz JK, Sadow PM, et al. Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma. Thyroid. 2020;30(9):1384-9.","journal-title":"Thyroid."},{"issue":"6","key":"9876_CR50","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-21-1259","volume":"186","author":"SG Waguespack","year":"2022","unstructured":"Waguespack SG, Drilon A, Lin JJ, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022;186(6):631-43.","journal-title":"Eur J Endocrinol."},{"key":"9876_CR51","doi-asserted-by":"crossref","unstructured":"Marczyk VR, Fazeli S, Dadu R, et al. NTRK Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy. JCO Precis Oncol. 2025;9(e2400321.","DOI":"10.1200\/PO-25-00552"},{"issue":"9","key":"9876_CR52","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth LJ, Sherman E, Robinson B, et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020;383(9):825-35.","journal-title":"N Engl J Med."},{"issue":"7","key":"9876_CR53","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","volume":"33","author":"S Filetti","year":"2022","unstructured":"Filetti S, Durante C, Hartl DM, et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol. 2022;33(7):674-84.","journal-title":"Ann Oncol."}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09876-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12022-025-09876-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09876-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:02:50Z","timestamp":1767862970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12022-025-09876-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9876"],"URL":"https:\/\/doi.org\/10.1007\/s12022-025-09876-x","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. J. Barletta is an editorial board member of the Endocrine Pathology journal. This article is based on a lecture given by Dr. J. Barletta at the Endocrine Pathology Society Companion meeting at the 2025 Annual The United States & Canadian Academy of Pathology (USCAP) meeting on March 23, 2025. Dr. M. Riascos has no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}